Literature DB >> 8937714

EndothelinB receptor-mediated contraction in human pulmonary resistance arteries.

K M McCulloch1, C C Docherty, I Morecroft, M R MacLean.   

Abstract

1. Using wire myography, we have examined the endothelin (ET) receptor subtypes mediating vasoconstriction to ET peptides in human pulmonary resistance arteries (150-200 microns, i.d.). 2. Cumulative concentration-response curves to ET-1, sarafotoxin 6c (SX6c) and ET-3 were constructed in the presence and absence of the selective antagonists FR 139317 (ETA-selective), BMS 182874 (ETA-selective) and BQ-788 (ETB-selective). 3. All agonists induced concentration-dependent contractions. However, the response curves to ET-1 were biphasic in nature. The first component demonstrated a shallow slope up to 1 nM ET-1. Above 1 nM ET-1 the response curve was markedly steeper. Maximum responses to ET-3 and SX6c were the same as those to 1 nM ET-1 and 30% of those to 0.1 microM ET-1. The order of potency, taking 0.3 microM as a maximum concentration was SX6c >> ET-3 > ET-1 (pEC50 values of: 10.75 +/- 0.27, 9.05 +/- 0.19, 8.32 +/- 0.08 respectively). Taking 1 nM ET-1 as a maximum, the EC50 for ET-1 was 10.08 +/- 0.13 and therefore ET-1 was equipotent to ET-3 and SX6c over the first component of the response curve. 4. Responses to ET-1 up to 1 nM were resistant to the effects of the ETA receptor antagonists, FR 139317 and BMS 182874 but were inhibited by the ETB receptor antagonist, BQ-788. Conversely, responses to ET-1 over 1 nM were inhibited by the ETA receptor antagonists, FR 139317 and BMS 182874 but unaffected by the ETB receptor antagonist, BQ-788. 5. The results suggest that at concentrations up to 1 nM, responses to ET-1 are mediated via the ETB receptor, whilst the responses to higher concentrations are mediated by ETA receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8937714      PMCID: PMC1915906          DOI: 10.1111/j.1476-5381.1996.tb16013.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Necessity of dual blockade of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi.

Authors:  T Fukuroda; S Ozaki; M Ihara; K Ishikawa; M Yano; T Miyauchi; S Ishikawa; M Onizuka; K Goto; M Nishikibe
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

2.  Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome.

Authors:  P Cacoub; R Dorent; G Maistre; P Nataf; A Carayon; C Piette; P Godeau; C Cabrol; I Gandjbakhch
Journal:  Am J Cardiol       Date:  1993-02-15       Impact factor: 2.778

3.  ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction.

Authors:  D M LaDouceur; M A Flynn; J A Keiser; E Reynolds; S J Haleen
Journal:  Biochem Biophys Res Commun       Date:  1993-10-15       Impact factor: 3.575

Review 4.  Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?

Authors:  A P Davenport; J J Maguire
Journal:  Trends Pharmacol Sci       Date:  1994-01       Impact factor: 14.819

5.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; M Yanagisawa; D Langleben; R P Michel; R Levy; H Shennib; S Kimura; T Masaki; W P Duguid; D J Stewart
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

6.  Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow.

Authors:  J A Vincent; R D Ross; J Kassab; J M Hsu; W W Pinsky
Journal:  Am J Cardiol       Date:  1993-05-15       Impact factor: 2.778

7.  Altered expression of ETB-receptor mRNA in the lung of rats with pulmonary hypertension.

Authors:  R Yorikane; T Miyauchi; S Sakai; T Sakurai; I Yamaguchi; Y Sugishita; K Goto
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

8.  Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores.

Authors:  S Karne; C K Jayawickreme; M R Lerner
Journal:  J Biol Chem       Date:  1993-09-05       Impact factor: 5.157

9.  Endothelin-1 in acute lung injury and the adult respiratory distress syndrome.

Authors:  D Langleben; M DeMarchie; D Laporta; A H Spanier; R D Schlesinger; D J Stewart
Journal:  Am Rev Respir Dis       Date:  1993-12

10.  Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

Authors:  B Seo; B S Oemar; R Siebenmann; L von Segesser; T F Lüscher
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

View more
  17 in total

1.  ET(A) receptors are the primary mediators of myofilament calcium sensitization induced by ET-1 in rat pulmonary artery smooth muscle: a tyrosine kinase independent pathway.

Authors:  A M Evans; H J Cobban; G F Nixon
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 2.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Endothelin-1 and its receptors on haemorrhoidal tissue: a potential site for therapeutic intervention.

Authors:  Varut Lohsiriwat; John H Scholefield; Vincent G Wilson; Michael R Dashwood
Journal:  Br J Pharmacol       Date:  2017-02-16       Impact factor: 8.739

5.  Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone.

Authors:  Graeme A Deuchar; Andrew Docherty; Margaret R MacLean; Martin N Hicks
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 6.  Chronic thromboembolic pulmonary hypertension.

Authors:  H J Reesink; J J Kloek; P Bresser
Journal:  Neth Heart J       Date:  2006-06       Impact factor: 2.380

7.  Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury.

Authors:  Karolina M Duthie; Patrick W F Hadoke; Nicholas S Kirkby; Eileen Miller; Jessica R Ivy; John F McShane; Win Gel Lim; David J Webb
Journal:  Br J Pharmacol       Date:  2015-04-23       Impact factor: 8.739

8.  5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor.

Authors:  I Morecroft; R P Heeley; H M Prentice; A Kirk; M R MacLean
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 9.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

10.  Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.

Authors:  Olga Rafikova; Ruslan Rafikov; Sanjiv Kumar; Shruti Sharma; Saurabh Aggarwal; Frank Schneider; Danny Jonigk; Stephen M Black; Stevan P Tofovic
Journal:  Free Radic Biol Med       Date:  2012-11-29       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.